Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of haemophilia

Emicizumab-kxwh: First Global Approval

(2018) Lesley J. Scott et al.   DRUGS

Translational Pharmacokinetic/Pharmacodynamic Characterization and Target-Mediated Drug Disposition Modeling of an Anti–Tissue Factor Pathway Inhibitor Antibody, PF-06741086

(2018) Chuenlei Parng et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers

(2018) M. Cardinal et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A: a phase 1b, randomized trial

(2018) Hermann Eichler et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from haemophilia patients and healthy subjects measured by the thrombin generation assay

(2017) E. K. Waters et al.   HAEMOPHILIA

Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy

(2017) K. John Pasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

(2017) Johannes Oldenburg et al.   NEW ENGLAND JOURNAL OF MEDICINE

The role of the tissue factor pathway in haemostasis and beyond

(2016) John H. McVey   CURRENT OPINION IN HEMATOLOGY

The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO

(2016) P. Collins et al.   HAEMOPHILIA

Extended half-life clotting factor concentrates: results from published clinical trials

(2016) G. Young et al.   HAEMOPHILIA

Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA®in prophylactic therapy

(2016) K. Varadi et al.   HAEMOPHILIA

When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH

(2016) K. Fischer et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The past and future of haemophilia: diagnosis, treatments, and its complications

(2016) Flora Peyvandi et al.   LANCET

Tissue Factor Pathway Inhibitor

(2015) Alan E. Mast   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Bioinformatic Characterization of Genes and Proteins Involved in Blood Clotting in Lampreys

(2015) Russell F. Doolittle   JOURNAL OF MOLECULAR EVOLUTION

Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial

(2015) P. Chowdary et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Biology of tissue factor pathway inhibitor

(2014) J. P. Wood et al.   BLOOD

Considerations in individualizing prophylaxis in patients with haemophilia A

(2014) L. A. Valentino   HAEMOPHILIA

Protein S Is a Cofactor for Platelet and Endothelial Tissue Factor Pathway Inhibitor-α but Not for Cell Surface–Associated Tissue Factor Pathway Inhibitor

(2013) Jeremy P. Wood et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Platelet protein disulfide isomerase is required for thrombus formation but not for hemostasis in mice

(2013) K. Kim et al.   BLOOD

The transition of prothrombin to thrombin

(2013) S. Krishnaswamy   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein

(2013) E. K. Waters et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Tissue factor pathway inhibitor-alpha inhibits prothrombinase during the initiation of blood coagulation

(2013) J. P. Wood et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Arthropathy in Patients with Moderate Hemophilia A: A Systematic Review of the Literature

(2013) Massimo Franchini et al.   SEMINARS IN THROMBOSIS AND HEMOSTASIS

Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model

(2012) I. Hilden et al.   BLOOD

Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)

(2012) Peter W. Collins et al.   BRITISH JOURNAL OF HAEMATOLOGY

Personalized prophylaxis

(2012) P. W. COLLINS   HAEMOPHILIA

Current prescription of prophylactic factor infusions and perceived adherence for children and adolescents with haemophilia: a survey of haemophilia healthcare professionals in the United States

(2012) C. D. THORNBURG et al.   HAEMOPHILIA

The potential role of synovial thrombomodulin in the pathophysiology of joint bleeds in haemophilia

(2012) Y. DARGAUD et al.   HAEMOPHILIA

Guidelines for the management of hemophilia

(2012) A. Srivastava et al.   HAEMOPHILIA

WFH: Closing the global gap - achieving optimal care

(2012) MARK W. SKINNER   HAEMOPHILIA

Association Between Physical Activity and Risk of Bleeding in Children With Hemophilia

(2012) Carolyn R. Broderick et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia

(2012) S. A. Maroney et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Aptamers and Their Biological Applications

(2012) Kyung-Mi Song et al.   SENSORS

Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia

(2012) Matthew Gissel et al.   THROMBOSIS RESEARCH

TFPI  is the GPI-anchored TFPI isoform on human endothelial cells and placental microsomes

(2011) T. J. Girard et al.   BLOOD

Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor

(2011) E. K. Waters et al.   BLOOD

Tissue factor pathway inhibitor: structure-function

(2011) George et al.   Frontiers in Bioscience-Landmark

Anti-Inhibitor Coagulant Complex Prophylaxis in Hemophilia with Inhibitors

(2011) Cindy Leissinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Kunitz-3 domain of TFPI-  is required for protein S-dependent enhancement of factor Xa inhibition

(2010) M. Ndonwi et al.   BLOOD

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

(2010) B. Mei et al.   BLOOD

A United Kingdom Haemophilia Centre Doctors’ Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A

(2010) Michael Richards et al.   BRITISH JOURNAL OF HAEMATOLOGY

First 20 years with recombinant FVIIa (NovoSeven)

(2010) U. HEDNER et al.   HAEMOPHILIA

Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice

(2009) S. A. MARONEY et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens

(2009) P. W. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A

(2008) P. W. COLLINS et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Mechanisms of Thrombus Formation

(2008) Bruce Furie et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of tissue factor pathway inhibitor by endothelial cells and platelets

(2008) Susan A. Maroney et al.   TRANSFUSION AND APHERESIS SCIENCE